Factorial trial for treating sleepy overweight or obese sleep apnea patients who cannot use standard treatments comparing hypocaloric diet with high protein/ low glycemic index diet for fat mass reduction and simultaneously comparing armodafinil with placebo for improving simulated driving ability and neuro-behavioural functioning.

Trial Profile

Factorial trial for treating sleepy overweight or obese sleep apnea patients who cannot use standard treatments comparing hypocaloric diet with high protein/ low glycemic index diet for fat mass reduction and simultaneously comparing armodafinil with placebo for improving simulated driving ability and neuro-behavioural functioning.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Obesity; Sleep apnoea syndrome
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms DEAR
  • Most Recent Events

    • 28 Jun 2012 Actual initiation date (22 Jun 2012) added and trial phase changed from IV to II/III as reported by Australian New Zealand Clinical Trials Registry record.
    • 28 Jun 2012 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry record.
    • 19 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top